Aytu Biopharma (AYTU) Accounts Payables (2011 - 2026)

Aytu Biopharma (AYTU) has 15 years of Accounts Payables data on file, last reported at $13.2 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 9.74% year-over-year to $13.2 million in Q1 2026; TTM through Mar 2026 was $13.2 million, a 9.74% increase from a year earlier, with the FY2025 full-year figure at $10.6 million, up 2.78% from the prior year.
• Accounts Payables for Q1 2026 stood at $13.2 million, down from $14.3 million in the prior quarter.
• Over the last five years, Accounts Payables for AYTU reached as high as $14.3 million in Q4 2025 and fell as low as $10.3 million in Q2 2024.
• Historically, Accounts Payables has averaged $12.0 million across 4 years, with a median of $12.0 million in 2025.
• Across the five-year window, Accounts Payables declined 23.48% in 2024 and advanced 21.88% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $10.5 million in 2023, then increased by 11.71% to $11.7 million in 2024, then gained by 21.88% to $14.3 million in 2025, then decreased by 7.33% to $13.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $13.2 million in Q1 2026, $14.3 million in Q4 2025, and $12.3 million in Q3 2025.